Valuation: Artiva Biotherapeutics, Inc.

Market Cap 421M 367M 347M 315M 590M 40.39B 592M 4.15B 1.6B 20.54B 1.58B 1.55B 66.08B P/E 2026 *
-3.32x
P/E 2027 * -3.18x
Enterprise Value 421M 367M 347M 315M 590M 40.39B 592M 4.15B 1.6B 20.54B 1.58B 1.55B 66.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
85.27%
Yield 2026 *
-
Yield 2027 * -
1 day+2.01%
1 week-15.75%
Current month-23.81%
1 month-26.28%
3 months-12.32%
6 months+48.45%
Current year+100.70%
1 week 8.35
Extreme 8.35
10.55
1 month 8.35
Extreme 8.35
12.08
Current year 3.62
Extreme 3.62
14.53
1 year 2.52
Extreme 2.52
14.53
3 years 1.47
Extreme 1.47
17.31
5 years 1.47
Extreme 1.47
17.31
10 years 1.47
Extreme 1.47
17.31
Manager TitleAgeSince
Chief Executive Officer 51 2021-01-04
President 63 2026-05-17
Chief Tech/Sci/R&D Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 40 2020-05-31
Director/Board Member 51 2021-01-04
Chairman 67 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Chief Executive Officer

425,000 0.8693%
9/10/26 Free

Chief Executive Officer

200,000 0.4091%
9/10/26 Free

Director

16,250 0.0332%
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%-15.75%+261.76% - 413M
+0.11%+2.71%+0.33%+28.59% 46.18B
-1.12%+1.78%+40.07%+27.26% 44.35B
-3.04%-6.29%+322.27%+517.36% 42.21B
-0.74%+1.25%+2.32%+67.94% 40.19B
-0.50%+0.67%+11.79%+40.51% 29.83B
-0.46%+4.22%+21.99%+124.21% 17.17B
-0.97%-10.17% - - 15.7B
-0.57%+8.12%+22.15%+38.93% 15.32B
-3.14%+31.91%-10.60% - 14.5B
Average -0.69%+2.23%+74.68%+120.69% 26.59B
Weighted average by Cap. -1.02%+2.71%+66.01%+131.93%

Financials

2026 *2027 *
Net sales - -
Net income -107M -93.3M -88.09M -80M -150M -10.27B -151M -1.06B -407M -5.22B -402M -393M -16.79B -135M -118M -111M -101M -190M -12.98B -190M -1.33B -515M -6.6B -508M -497M -21.23B
Net Debt - -
Logo Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Employees
115
Date Price Change Volume
26-09-18 US$8.610 +2.01% 2,208,257
26-09-17 US$8.440 -1.86% 456,517
26-09-16 US$8.600 -3.48% 516,987
26-09-15 US$8.910 -12.13% 584,582
26-09-14 US$10.14 -0.78% 243,866
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.610USD
Average target price
35.80USD
Spread / Average Target
+315.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARTV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!